2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - 260-262
Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Immunotherapy, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Study Population, Animal Model
PAPER

656 Low affinity CD3 engagement with Etentamig (CD3xBCMA) uncouples NFkB-driven inflammatory cytokine production from anti-myeloma T-cell cytotoxicity, reducing risk of cytokine release syndrome

Valerie Robinson, Yuna Son2, Christine Mantis3, Marion L Refici4, Adam Chervin5, Claudie Hecquet6, Rajvineeth Kumar Pothacamury, MD7, Anders Svensson, MD8, Jovian Yu, MD, MS, MBA9, PK Epling-Burnette, PhD, PharmD10, Jeremy A. Ross, PhD, MBA11, Aarif Ahsan, PhD12, David Sharon, PhD13
1 AbbVie Inc., North Chicago, Illinois, United States
2 AbbVie Inc., North Chicago, Illinois, United States
3 AbbVie Inc., North Chicago, Illinois, United States
4 AbbVie Inc., North Chicago, Illinois, United States
5 AbbVie Inc., North Chicago, Illinois, United States
6 AbbVie Inc., North Chicago, Illinois, United States
7 AbbVie Inc., North Chicago, Illinois, United States
8 AbbVie Inc., North Chicago, Illinois, United States
9 AbbVie Inc., North Chicago, Illinois, United States
10 AbbVie Inc., North Chicago, Illinois, United States
11 AbbVie Inc., North Chicago, Illinois, United States
12 AbbVie Inc., North Chicago, Illinois, United States
13 AbbVie Inc., North Chicago, Illinois, United States

Introduction: Etentamig is being developed as a next-generation differentiated B-cell maturation antigen (BCMA) x CD3 bispecific T-cell engager, optimized for convenient monthly (Q4W) dosing from the start, and composed of a bivalent BCMA-binding domain with high avidity, and a low-affinity CD3 binding domain potentially reducing cytokine release syndrome (CRS) and infection rates. Preclinical studies with etentamig have shown potent T-cell–dependent cytotoxicity with less cytokine release compared to high-affinity CD3 anti-BCMA bispecific antibodies, suggesting reduced CD3 affinity may broaden its therapeutic index (TI). However, the molecular basis for the dissociation between CRS-related cytokine release and myeloma T-cell cytotoxicity has not been fully defined. Here, we present clinical biomarker results and supporting preclinical data clarifying the underlying basis for decoupling potent tumor cell killing with limited inflammatory cytokine release related to low-affinity CD3 binding.

Methods: Peripheral blood and serum samples from patients with relapsed/refractory (RR) MM patients enrolled in Phase 1 studies M22-466 (NCT03933735) and M24-108 (NCT05650632) were collected at baseline, on treatment, and at progression, and analyzed by flow cytometry for immune cell populations and Luminex® for cytokine quantification. Purified CD138-negative (non-tumor immune cells) from baseline bone marrow aspirate samples were subjected to bulk RNA sequencing. In preclinical studies, etentamig was compared with a high-affinity CD3×BCMA comparator (teclistamab biosimilar), a CD3 high-affinity etentamig variant (HA-etentamig), and an isotype control AB095. T-cell binding, cytotoxicity, and cytokine production were assessed in ex vivo co-culture assays across a broad concentration range. TI was calculated as a ratio of tumor lysis area under the curve (AUC) to cytokine AUC. Bulk and single-cell RNA sequencing were performed on purified T-cells. Differential gene expression, pathway enrichment, and gene signatures were evaluated for association with CRS severity using ssGSEA and nonparametric testing.

Results: In the optimized etentamig dosing group (2 mg step-up dose/60 mg Q4W, M24-108 study), peak levels of key CRS-related cytokines, IL-6, IL-8, and TNFα, were lower compared to the M22-466 study (60 mg Q4W without SUD), consistent with the overall lower CRS rate across all groups (26% Grade 1, 4% Grade 2, no Gr3+). Importantly, T-cell function was not affected as etentamig still triggered strong CD8+ effector T cell activation (%CD69+) with low levels of exhaustion (%PD1+TIM3+) in responders across nine treatment cycles. Subsequent preclinical studies investigated the mechanistic basis by which cytokine release due to differential CD3 binding affinity can be decoupled from T-cell cytotoxicity.

Consistent with its low CD3 binding affinity, etentamig showed a >100-fold reduction in T-cell binding compared to the teclistamab biosimilar and HA-etentamig at equimolar concentrations. While comparable maximal tumor cytotoxicity was observed, etentamig showed a broader therapeutic index (TI; 0.82 +/- 0.04) than both the teclistamab biosimilar (0.40 +/- 0.01, P=0.0088) and HA-etentamig (0.20 +/- 0.01, P<0.0001), based on IL-6 levels, with similar results for IL-2 and TNFα. Single-cell RNA sequencing of etentamig-, HA-etentamig-, and control-treated cells resolved 15 unique T-cell clusters. Relative to etentamig, HA-etentamig increased the proportion of two clusters, both representing activated CD4+ T cells, including TNFα-induced NFκB pathway (26/50 genes adjusted P=1.33x10-31). Notably, an NFκB pathway inhibitor reduced HA-etentamig-associated cytokine release without compromising tumor killing. In M22-466 and M24-108 study, elevated baseline gene expression signatures based on the two activated CD4 single-cell clusters were associated with a greater risk of Grade >/ 2 CRS.

Conclusions: The reduced CRS risk observed with etentamig is attributed to its low-affinity CD3 binding domain, which reduces NFκB-driven activation of CD4+ T-cells while preserving potent anti-myeloma cytotoxicity. Thus, cytokine release and cytotoxicity operate through distinct T-cell activation thresholds and can be functionally dissociated through CD3 affinity optimization. These findings provide mechanistic evidence for etentamig’s differentiated design and support its potential to deliver potent anti-tumor efficacy with a reduced inflammatory toxicity profile.

Valerie Robinson: AbbVie - Current equity holder in publicly-traded company; AbbVie - Stock (publicly traded); AbbVie - Current Employment